Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Vernalis PLC (VER)

  Print      Mail a friend       Annual reports

Tuesday 27 March, 2012

Vernalis PLC

Cancellation of Listing/Proposed Admission to AIM

RNS Number : 1093A
Vernalis PLC
27 March 2012

27 March 2012


Cancellation of Listing and proposed admission to AIM


Vernalis plc (LSE: VER) (the "Company") announces that it has requested the cancellation of its listing on the Official List of the FSA.  Such cancellation will be with effect from 08.00 on 27 April 2012.


Following Admission of the New Ordinary Shares pursuant to the Firm Placing and Placing and Open Offer as described in the Prospectus sent to Shareholders on 10 February 2012, the Company confirms it is in breach of Listing Rule 6.1.19 (the "Free Float requirement").  On 28 February 2012, Shareholders voted in favour of the Resolutions which, inter alia, gave authority to the Directors to cancel the Company's current listing and seek admission to AIM if, on Admission, the Free Float requirement was breached.


The Company confirms that it has given notice to the UKLA to cancel its listing on the Official List and to the LSE to cancel its Ordinary Shares from trading on the LSE's main market for listed securities.  Earlier today, the LSE notified to RNS a Schedule One pre-admission announcement of the Company's application for admission to AIM. 


The Company's listing on the Official List will be cancelled effective at 08.00 on 27 April 2012 and it is anticipated that admission to trading on AIM will occur at the same time and on the same date.


Nomura Code Securities Limited will act as the Company's Nominated Adviser (Nomad) pursuant to the AIM rules.


Capitalised terms used (but not defined) in this announcement have the same meanings as in the Prospectus sent to shareholders on 10 February 2012 unless the context requires otherwise.


Vernalis plc

+44 (0) 118 989 9360

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

Nomura Code Securities:

+44 (0) 20 7776 1200

Juliet Thompson, Managing Director

Brunswick Group

+44 (0) 20 7404 5959

Jon Coles

Kristin Shine

Taylor Rafferty

+44 (0) 20 7614 2900

Rob Newman

Faisal Kanth


About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development.  The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes.  Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations.  Our technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, GSK, Lundbeck, Menarini, Novartis and Servier.


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t